LGALS3 and asthma: This study needs to be confirmed by others but it indicates that Gal-3 may be considered as new asthma-related biomarker, useful for patient stratification for therapy, in addition to the other biomarkers already known, such as the fractional exhaled nitric oxide (FeNO) levels, the blood/sputum eosinophil counts, the serum periostin levels, the smooth muscle proteins and the keratins.